Systems pharmacology assessment of the 5-fluorouracil pathway

Pharmacogenomics

Volumn 12, Issue 3, 2011, Pages 341-350

  Muhale, Filipe A ^a,b   Wetmore, Barbara A ^b   Thomas, Russell S ^a,b   McLeod, Howard L ^a  

^a UNC Hamner Institute for Drug Safety Sciences   (United States)

^b HAMNER INSTITUTES FOR HEALTH SCIENCES   (United States)

Author keywords

5 fluorouracil pathway; candidate genes prioritization; colon cancer; pharmacogenomics; RNAi

Indexed keywords

DIHYDROFOLATE REDUCTASE; DIHYDROPYRIMIDINASE; FLUOROURACIL; GENE PRODUCT; PROTEIN DTYMK; PROTEIN DUT; PROTEIN FPGS; PROTEIN GGH; PROTEIN NME1; PROTEIN NT5C; PROTEIN RRM1; PROTEIN UCK2; PROTEIN UNG; SHORT HAIRPIN RNA; SYNTHETASE; THYMIDYLATE SYNTHASE; UNCLASSIFIED DRUG; URIDINE MONOPHOSPHATE SYNTHASE;

ARTICLE; CANCER CELL CULTURE; CELL STRAIN HCT116; CELL STRAIN HT29; COLORECTAL CANCER; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG SENSITIVITY; GENE SILENCING; GENETIC ANALYSIS; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IC 50; LOSS OF FUNCTION MUTATION; MUTATIONAL ANALYSIS; PHARMACOGENOMICS; PHENOTYPE; RNA INTERFERENCE; SIGNAL TRANSDUCTION;

ANTIMETABOLITES, ANTINEOPLASTIC; APOPTOSIS; COLORECTAL NEOPLASMS; DRUG RESISTANCE, NEOPLASM; FLUOROURACIL; HCT116 CELLS; HUMANS; METABOLIC NETWORKS AND PATHWAYS; RNA, SMALL INTERFERING; THYMIDYLATE SYNTHASE;

EID: 79953244942     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.10.188     Document Type: Article

References (42)

1. Santi DV, McHenry CS: 5-fuoro-2-deoxyuridylate: covalent complex with thymidylate synthetase. Proc. Natl Acad. Sci. USA 69(7), 1855-1857 (1972).
2. De Gramont A, Figer A, Seymour M et al.: Leucovorin and fuorouracil with or without oxaliplatin as frst-line treatment in advanced colorectal cancer. J. Clin. Oncol. 18(16), 2938-2947 (2000). (Pubitemid 30644117)
3. Tol J, Koopman M, Cats A et al.: Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer. N. Engl. J. Med. 360(6), 563-572 (2009).
4. Cassidy J, Saltz L, Giantonio B, Kabbinavar F, Hurwitz H, Rohr UP: Effect of bevacizumab in older patients with metastatic colorectal cancer: pooled ana lysis of four randomized studies. J. Cancer Res. Clin. Oncol. 136(5), 737-743 (2010).
5. Hurwitz HI, Fehrenbacher L, Hainsworth JD et al.: Bevacizumab in combination with fuorouracil and leucovorin: an active regimen for frst-line metastatic colorectal cancer. J. Clin. Oncol. 23(15), 3502-3508 (2005).
6. Diasio RB, Harris BE: Clinical parmacology of 5-fuorouracil. Clin. Pharmacokinet. 16(4), 215-237 (1989).
7. Heggie GD, Sommadossi JP, Cross DS, Huster WJ, Diasio RB: Clinical pharmacokinetics of 5-fuorouracil and its metabolites in plasma, urine, and bile. Cancer Res. 47(8), 2203-2206 (1987). (Pubitemid 17074634)
8. Yen JL, McLeod HL: Should DPD ana lysis be required prior to prescribing fuoropyrimidines? Eur. J. Cancer 43(6), 1011-1016 (2007). (Pubitemid 46483039)
9. Etienne M, Lagrange J, Dassonville O et al.: Population study of dihydropyrimidine dehydrogenase in cancer patients. J. Clin. Oncol. 12(11), 2248-2253 (1994). (Pubitemid 24346691)
10. Lu Z, Zhang R, Carpenter JT, Diasio RB: Decreased dihydropyrimidine dehydrogenase activity in a population of patients with breast cancer: implication for 5-fuorouracil-based chemotherapy. Clin. Cancer Res. 4(2), 325-329 (1998). (Pubitemid 28122745)
11. Ridge SA, Sludden J, Brown O et al.: Dihydropyrimidine dehydrogenase pharmacogenetics in Caucasian subjects. Br. J. Clin. Pharmacol. 46(2), 151-156 (1998). (Pubitemid 28342786)
12. Öfverholm A, Arkblad E, Skrtic S, Albertsson P, Shubbar E, Enerbäck C: Two cases of 5-fuorouracil toxicity linked with gene variants in the DPYD gene. Clin. Biochem. 43(3), 331-334 (2010).
13. Johnson MR, Wang K, Tillmanns S, Albin N, Diasio RB: Structural organization of the human dihydropyrimidine dehydrogenase gene. Cancer Res. 57(9), 1660-1663 (1997). (Pubitemid 27199654)
14. Yu J, McLeod HL: Methylation of the DPYD promoter and dihydropyrimidine dehydrogenase defciency. Clin. Cancer Res. 12(12), 3864-3864 (2006).
15. Sumi S, Imaeda M, Kidouchi K et al.: Population and family studies of dihydropyrimidinuria: prevalence, inheritance mode, and risk of fuorouracil toxicity. Am. J. Med. Genet. 78(4), 336-340 (1998).
16. Van Kuilenburg AB, Meinsma R, Zonnenberg BA et al.: Dihydropyrimidinase defciency and severe 5-fuorouracil toxicity. Clin. Cancer Res. 9(12), 4363-4367 (2003). (Pubitemid 37248392)
17. Thomas HR, Ezzeldin HH, Guarcello V, Mattison LK, Fridley BL, Diasio RB: Genetic regulation of b-ureidopropionase and its possible implication in altered uracil catabolism. Pharmacogenet. Genomics 18(1), 25-35 (2008). (Pubitemid 351161646)
18. Van Kuilenburg AB, Meinsma R, Beke E et al.: b-ureidopropionase defciency: an inborn error of pyrimidine degradation associated with neurological abnormalities. Hum. Mol. Genet. 13(22), 2793-2801 (2004). (Pubitemid 39562543)
19. Yaplito-Lee J, Pitt J, Meijer J, Zoetekouw L, Meinsma R, Van Kuilenburg AB: b-ureidopropionase defciency presenting with congenital anomalies of the urogenital and colorectal systems. Mol. Genet. Metab. 93(2), 190-194 (2008).
20. Pinedo H, Peters G: Fluorouracil: biochemistry and pharmacology. J. Clin. Oncol. 6(10), 1653-1664 (1988).
21. Ghoshal K, Jacob ST: Specifc inhibition of pre-ribosomal RNA processing in extracts from the lymphosarcoma cells treated with 5-fuorouracil. Cancer Res. 54(3), 632-636 (1994). (Pubitemid 24068314)
22. Zhao X, Yu YT: Incorporation of 5-fuorouracil into U2 snRNA blocks pseudouridylation and pre-mRNA splicing in vivo. Nucl. Acids Res. 35(2), 550-558 (2007). (Pubitemid 46232071)
23. Johnston PG, Lenz HJ, Leichman CG et al.: Thymidylate synthase gene and protein expression correlate and are associated with response to 5-fuorouracil in human colorectal and gastric tumors. Cancer Res. 55(7), 1407-1412 (1995).
24. Leichman C, Lenz H, Leichman L et al.: Quantitation of intratumoral thymidylate synthase expression predicts for disseminated colorectal cancer response and resistance to protracted-infusion fuorouracil and weekly leucovorin. J. Clin. Oncol. 15(10), 3223-3229 (1997). (Pubitemid 27419335)
25. Marsh S: Thymidylate synthase pharmacogenetics. Invest. New Drugs 23(6), 533-537 (2005). (Pubitemid 43162472)
26. Wang TL, Diaz LA, Romans K et al.: Digital karyotyping identifes thymidylate synthase amplifcation as a mechanism of resistance to 5-fuorouracil in metastatic colorectal cancer patients. Proc. Natl Acad. Sci. USA 101(9), 3089-3094 (2004). (Pubitemid 38327739)
27. Oguri T, Achiwa H, Bessho Y et al.: The role of thymidylate synthase and dihydropyrimidine dehydrogenase in resistance to 5-fuorouracil in human lung cancer cells. Lung Cancer 49(3), 345-351 (2005). (Pubitemid 41139147)
28. Jensen SA, Vainer B, Sørensen JB: The prognostic signifcance of thymidylate synthase and dihydropyrimidine dehydrogenase in colorectal cancer of 303 patients adjuvantly treated with 5-fuorouracil. Int. J. Cancer 120(3), 694-701 (2007). (Pubitemid 44969043)
29. Soong R, Shah N, Salto-Tellez M et al.: Prognostic signifcance of thymidylate synthase, dihydropyrimidine dehydrogenase and thymidine phosphorylase protein expression in colorectal cancer patients treated with or without 5-fuorouracil-based chemotherapy. Ann. Oncol. 19(5), 915-919 (2008). (Pubitemid 351627307)
30. Bunz F, Hwang PM, Torrance C et al.: Disruption of p53 in human cancer cells alters the responses to therapeutic agents. J. Clin. Invest. 104(3), 263-269 (1999).
31. Liang JT, Huang KC, Cheng YM et al.: P53 overexpression predicts poor chemosensitivity to high-dose 5-fuorouracil plus leucovorin chemotherapy for stage IV colorectal cancers after palliative bowel resection. Int. J. Cancer 97(4), 451-457 (2002).
32. Jakob C, Liersch T, Meyer WP et al.: Immunohistochemical analysis of thymidylate synthase, thymidine phosphorylase, and dihydropyrimidine dehydrogenase in rectal cancer (cUICC II/III): correlation with histopathologic tumor regression after 5-fuorouracil-based long-term neoadjuvant chemoradiotherapy. Am. J. Surg. Pathol. 29(10), 1304-1309 (2005). (Pubitemid 41368765)
33. Moffat J, Grueneberg DA, Yang X et al.: A lentiviral RNAi library for human and mouse genes applied to an arrayed viral high-content screen. Cell 124(6), 1283-1298 (2006).
34. Jackson AL, Linsley PS: Recognizing and avoiding siRNA off-target effects for target identifcation and therapeutic application. Nat. Rev. Drug Discov. 9(1), 57-67 (2010).
35. Dydensborg AB, Herring E, Auclair J, Tremblay E, Beaulieu JF: Normalizing genes for quantitative RT-PCR in differentiating human intestinal epithelial cells and adenocarcinomas of the colon. Am. J. Physiol. Gastrointest. Liver Physiol. 290(5), G1067-G1074 (2006).
36. Cheng A, Johnson CL, Ford LP: A step-by-step procedure to analyze the effcacy of siRNA using real-time PCR. Methods Mol. Biol. 419, 303-316 (2008)
37. Zhang JH, Chung TD, Oldenburg KR: A simple statistical parameter for use in evaluation and validation of high throughput screening assays. J. Biomol. Screen 4(2), 67-73 (1999). (Pubitemid 29278954)
38. Kidd EA, Yu J, Li X, Shannon WD, Watson MA, McLeod HL: Variance in the expression of 5-fuorouracil pathway genes in colorectal cancer. Clin. Cancer Res. 11(7), 2612-2619 (2005). (Pubitemid 40569461)
39. Koizumi W, Tanabe S, Azuma M et al.: Impacts of fuorouracil-metabolizing enzymes on the outcomes of patients treated with S-1 alone or S-1 plus cisplatin for frst-line treatment of advanced gastric cancer. Int. J. Cancer 126(1), 162-170 (2010).
40. Ishikawa M, Miyauchi T, Kashiwagi Y: Clinical implications of thymidylate synthetase, dihydropyrimidine dehydrogenase and orotate phosphoribosyl transferase activity levels in colorectal carcinoma following radical resection and administration of adjuvant 5-FU chemotherapy. BMC Cancer, 8(1), 188 (2008).
41. Carreras CW, Santi DV: The catalytic mechanism and structure of thymidylate synthase. Ann. Rev. Biochem. 64(1), 721-762 (1995).
42. Watters JW, Kraja A, Meucci MA, Province MA, McLeod HL: Genome-wide discovery of loci infuencing chemotherapy cytotoxicity. Proc. Natl Acad. Sci. USA 101(32), 11809-11814 (2004). (Pubitemid 39095376)